What's Going On With TG Therapeutics (TGTX) Stock?
Portfolio Pulse from Erica Kollmann
TG Therapeutics, Inc. (NASDAQ:TGTX) shares are moving higher after the company reported first quarter product revenue from its drug Briumvi at $7.8 million and projected continued revenue growth. The stock is also receiving attention from retail investors and has a considerable short interest of 18.59%.
July 07, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TG Therapeutics' stock is rising after reporting Q1 revenue from its drug Briumvi and projecting continued growth. The stock is also trending among retail investors and has a high short interest.
The rise in TG Therapeutics' stock can be attributed to the positive Q1 revenue report and the projected growth for its drug Briumvi. The high short interest indicates that many investors are betting against the stock, which could lead to a short squeeze and further increase the stock price. The attention from retail investors could also contribute to the stock's upward movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100